Retension Pharmaceuticals

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and related cardiovascular disorders. Its lead product candidate, RTN-001, is an orally administered, once-daily PDE5 inhibitor being evaluated for patients with uncontrolled or resistant hypertension. The company’s work centers on addressing persistent blood-pressure management challenges through pharmaceutical development and clinical research. Retension Pharmaceuticals, Inc. operates within the cardiovascular therapeutics market, serving the broader healthcare ecosystem of patients, physicians, research institutions, and pharmaceutical partners. Based in Virginia, the company represents a specialized biotechnology business whose activities are concentrated on advancing a targeted drug candidate through clinical development rather than marketing an established portfolio of commercial medicines. Its market role is tied to the development of potential treatment options for hypertension, a widespread cardiovascular condition associated with significant demands on healthcare systems and long-term disease management.